View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Services
  2. Clinical Trials
September 5, 2018updated 12 Aug 2019 11:22am

RedHill Biopharma completes enrolment in Phase III trial of Talicia

RedHill Biopharma has completed patient enrolment in the Phase III ERADICATE Hp2 study of Talicia (RHB-105) in comparison with a dual therapy regimen of amoxicillin and omeprazole for the treatment of H. pylori infection.

RedHill Biopharma has completed patient enrolment in the Phase III ERADICATE Hp2 study of Talicia (RHB-105) in comparison with a dual therapy regimen of amoxicillin and omeprazole for the treatment of H. pylori infection.

The two-arm, randomised, double-blind, active comparator confirmatory trial has enrolled a total of 455 non-investigated dyspepsia patients with confirmed H. pylori infection at 55 clinical sites across the US.

The patients were randomised in a 1:1 ratio to be given four capsules of either Talicia or the active comparator, three times a day for 14 days.

The primary endpoint of the trial is eradication of H. pylori infection at 43 through to 71 days after the beginning of treatment.

Top-line results from the trial are scheduled to be released later this year.

“Top-line results from the trial are scheduled to be released later this year.”

Depending upon the success of the trial and additional regulatory feedback, the ERADICATE Hp2 trial is expected to complete the package necessary for filing a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for Talicia early next year.

Talicia has already received the Qualified Infectious Disease Product (QIDP) designation from the FDA.

It is a fixed-dose oral combination therapy of two antibiotics and a proton pump inhibitor (PPI) in an oral capsule with a planned indication for the treatment of H. pylori infection, irrespective of ulcer status.

RedHill Biopharma noted that the first Phase III study of Talicia, titled ERADICATE Hp study, has successfully met its primary endpoint of superiority over historical standard-of-care (SoC) eradication rate of 70%.

H.pylori bacterial infection is a leading cause of chronic gastritis, peptic ulcer disease, gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma.

The infection is estimated to have affected more than half of the adult population across the globe.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena